SAVA Share Price Performance
US$3.25
-0.19 (-5.66%)
Price US$3.25
Share Pricen/a
Cassava Sciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
SAVA Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Cassava Sciences, Inc. Key Details
About SAVA
- Founded
- 1998
- Employees
- 30
- CEO
- WebsiteView website
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
